Nirmish Singla is an Oncologist in Lutherville, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Arvin K. George, MD, is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers, with particular sub-specialization in kidney and prostate cancers. His clinical interests and expertise are in image-guided therapeutics, and minimally-invasive ablative/surgical techniques for prostate and kidney cancer. These include laparoscopic and robotic surgery, in addition to cryoablation, high-intensity focused ultrasound ablation, nanoparticle directed laser ablation, laser interstitial thermal therapy, and bipolar radiofrequency ablation. Dr. George obtained his medical degree from the Royal College of Surgeons in Ireland, followed by a urology residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his endourology/minimally-invasive and robotic surgery fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute, National Institutes of Health. He then joined the clinical facility at the University of Michigan, Ann Arbor, where he directed the Prostate Cancer Programs from 2019 through 2023. Dr. George participates extensively in the discovery of urologic science and evaluation of urologic care and has co-authored over 80 peer reviewed publications. Additionally, he has authored 11 chapters in medical education books. Dr. George sees patients in clinic throughout the Baltimore region and also is available for virtual appointments for patients in Maryland, Washington D.C., New York and Michigan. Dr. George is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Arun Rai, M.D., M.B.A., M.S., is a urologist who specializes in minimally invasive surgery and endourology and has extensive training to treat patients with adrenal cancer, kidney cancer, ureteral cancer and prostate cancer. In addition, he also specializes in treating patients with BPH, kidney stones and bladder stones. Dr. Rai earned both his undergraduate and medical degrees through the highly selective seven-year accelerated medical education program at Boston University School of Medicine. Dr. Rai went on to complete a general surgery internship at Baylor College of Medicine, where he then also completed his urology residency. Dr. Rai continued his training at the Northwell Health’s Smith Institute for Urology by completing a fellowship in Endourology and Minimally Invasive Surgery. During this time, he also received a dual MBA/MS in Healthcare Leadership Weill Cornell Graduate School of Medical Sciences and Cornell University. In addition to caring for patients, Dr. Rai serves as Clinical Director for the Brady Urological Institute's Quantitative Data Sciences division. His research focuses on developing the next generation of surgical technology, focusing on artificial intelligence and machine learning for optimizing clinical care. He strongly believes that surgeons should have an active role in the development of the next generation of tools for the optimal treatment of patients. He has authored several publications, with topics including patient safety in the operating room, long-term outcomes of subcapsular renal hematoma, pelvi-ureteric junction obstruction and featured in journals such as Urology and the Journal of Endourology. Dr. Rai is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Kidney Stones, Horseshoe Kidney, Boils, Ureteroscopy, and Lithotripsy.

Ahmed Ghazi is an associate professor of urology at the Johns Hopkins University School of Medicine. He is the Director of Surgical Simulation Training and the Division of Minimally Invasive and Robotic Surgery within the Johns Hopkins Brady Urological Institute. Dr. Ghazi specializes in urologic surgical oncology using the latest techniques of minimally invasive surgery for prostate, kidney, bladder, ureteral and other genitourinary organ cancers. He also as specializes in minimal invasive treatment of complex stones of the urinary tract. Dr. Ghazi is a pioneer in the field of patient-specific surgical simulation, which has applications for training future surgeons as well as improving outcomes for patients through individualized modeling. When planning for a complex surgery, Dr. Ghazi constructs 3D models of the patient’s anatomy in order to plan and rehearse surgery prior to the actual surgery. These models span from digital renderings to tangible models used to practice the critical components of your surgery. Dr. Ghazi received his medical degree from Cairo University in Egypt in 2000, where he also completed his surgery training and urology residency. From there, Dr. Ghazi completed a laparoscopic fellowship in Paris, France in 2008, followed by a second laparoscopic fellowship in Austria in 2009. While practicing in Europe, Dr. Ghazi was accepted to the European Board of Urology. Dr. Ghazi continued his training at the University of Rochester, New York through a two-year fellowship in the robotic treatment of various urologic cancers. He then joined the staff at the urology department of University of Rochester in 2012 where he continued to practice until joining Johns Hopkins Medicine. Dr. Ghazi believes in a reciprocal relationship between innovation, surgery & research where each informs and strengthens the others. He strives to adopt innovative surgical technologies that are evidence-based, benefit his patients and translate directly to improved patient outcomes. Dr. Ghazi is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Kidney Stones, Boils, Prostatectomy, and Nephrectomy.

Naren Nimmagadda, M.D., is an assistant professor of urology at the Johns Hopkins University School of Medicine. He treats a wide range of benign and malignant urological conditions. As a fellowship trained urologist in endourologic and laparoscopic surgery, his practice focuses on treated voiding issues related to BPH through Holmium Laser Enucleation of the Prostate (HoLEP), an alternative to transurethral resection of the prostate (TURP). Dr. Nimmagadda also specializes in treating kidney, ureteral and bladder stones via shockwave lithotripsy, endoscopic and percutaneous techniques. Dr. Nimmagadda is the Endourology, Minimally Invasive Urology Fellowship Program Director. Dr. Nimmagadda attended medical school at the University of Maryland School of Medicine. Following medical school, Dr. Nimmagadda completed a general surgery internship and residency in urology at Massachusetts General Hospital. He then completed a fellowship in endourology and laparoscopic surgery at Vanderbilt University Medical Center. Following graduation, Dr. Nimmagadda served on the Vanderbilt University Medical Center’s Department of Urology faculty as an instructor. Dr. Nimmagadda has research interest in the intersection of urology and technological innovation. Dr. Nimmagadda is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Kidney Stones, Enlarged Prostate (BPH), UPJ Obstruction, Ureteroscopy, and Lithotripsy.

Dr. Brian Matlaga is a Professor of Urology at Johns Hopkins University School of Medicine and also is the Director of the Stephens Center for Stone Disease as well as the Executive Vice Chair of the James Buchanan Brady Urological Institute. Dr. Matlaga is an internationally recognized expert in the medical and surgical management of patients with urinary stone disease. A frequent contributor to the medical press, with over 180 peer-reviewed publications, Dr. Matlaga’s research has received national and international awards. Dr. Matlaga sits on numerous editorial boards as well as advisory committees and guidelines panels for the American Urological Association, the American Board of Urology, the Endourological Society, and the National Institutes of Health, amongst others. Dr. Matlaga serves as Executive Medical Director of Clinical Affairs for Johns Hopkins Medicine International, the arm of Johns Hopkins Medicine that manages its global presence. In this capacity, he delivers clinical care as well as project leadership across the globe. Dr. Matlaga is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Kidney Stones, Bladder Stones, Boils, Ureteroscopy, and Lithotripsy.

Dr. Herati is a urologist with fellowship training in male infertility and andrology. He has specialized training to perform complex reconstructions of the reproductive system, including vasectomy reversal with vasovasostomy and vasoepididymostomy. Additionally, he has an interest in treating patients with chronic prostatitis and pelvic pain, as well as patients experiencing low testosterone, erectile dysfunction, Peyronie’s disease and benign prostatic hyperplasia (BPH). Of note, he has the ability to perform fertility treatments on patients who have experienced spinal cord injuries using nonsurgical methods of sperm extraction. Dr. Herati believes in an individualized approach to care that addresses the whole patient. He invests significant time into building a rapport with his patients so that they feel comfortable opening up about these issues, allowing him to accurately identify and manage each patient’s needs. His research interests include decoding the genetic basis of male infertility, investigating the impact of referred pain from peripheral nerves to the bladder, and characterizing the effects of low testosterone on prostate inflammation and PSA screening. Dr. Herati sees patients at both the Johns Hopkins Hospital and The Johns Hopkins Bayview Medical Center. Videos Amin Herati, M.D.Urologist. Dr. Herati is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Enlarged Prostate (BPH), Varicocele, Hypogonadism, Nephrectomy, and Prostatectomy.

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Richard Huslig is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Huslig is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, Lung Cancer, and Colorectal Cancer. Dr. Huslig is currently accepting new patients.

Daniel Dietrick is an Urologist in Towson, Maryland. Dr. Dietrick is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Ureteroscopy, and Vasectomy.

Alan Geringer is an Urologist and an Addiction Medicine provider in Towson, Maryland. Dr. Geringer is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Geringer is currently accepting new patients.

Paul Celano is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Celano is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.